Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jul;26(1):103–106. doi: 10.1111/j.1365-2125.1988.tb03372.x

The effect of thyrotoxicosis on isoniazid acetylation.

M D Littley 1, A Hutchings 1, B P Spragg 1, P A Routledge 1, J H Lazarus 1
PMCID: PMC1386508  PMID: 2462441

Abstract

Isoniazid acetylation was assessed in 10 thyrotoxic patients before and after standard antithyroid therapy. The group contained five fast and five slow acetylators and all remained within the same phenotypic classification when rendered euthyroid. There was no significant change in the elimination half-life of isoniazid between thyrotoxicosis and euthyroidism for the group as a whole or for fast and slow acetylators considered separately. Thyrotoxicosis does not appear to be an important determinant of isoniazid acetylation in man.

Full text

PDF
103

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eichelbaum M. Drug metabolism in thyroid disease. Clin Pharmacokinet. 1976;1(5):339–350. doi: 10.2165/00003088-197601050-00002. [DOI] [PubMed] [Google Scholar]
  3. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gold C. H., Buchanan N., Tringham V., Viljoen M., Strickwold B., Moodley G. P. Isoniazid pharmacokinetics in patients in chronic renal failure. Clin Nephrol. 1976 Aug;6(2):365–369. [PubMed] [Google Scholar]
  5. Hashem N., Khalifa S., Nour A. The frequency of isoniazid acetylase enzyme deficiency among Egyptians. Am J Phys Anthropol. 1969 Jul;31(1):97–101. doi: 10.1002/ajpa.1330310114. [DOI] [PubMed] [Google Scholar]
  6. Hutchings A., Monie R. D., Spragg B., Routledge P. A. A method to prevent the loss of isoniazid and acetylisoniazid in human plasma. Br J Clin Pharmacol. 1983 Feb;15(2):263–266. doi: 10.1111/j.1365-2125.1983.tb01496.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hutchings A., Monie R. D., Spragg B., Routledge P. A. High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids. J Chromatogr. 1983 Oct 14;277:385–390. doi: 10.1016/s0378-4347(00)84863-x. [DOI] [PubMed] [Google Scholar]
  8. Hutchings A., Routledge P. A. A simple method for determining acetylator phenotype using isoniazid. Br J Clin Pharmacol. 1986 Sep;22(3):343–345. doi: 10.1111/j.1365-2125.1986.tb02897.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jeanes C. W., Schaefer O., Eidus L. Inactivation of isoniazid by Canadian Eskimos and Indians. Can Med Assoc J. 1972 Feb 19;106(4):331–335. [PMC free article] [PubMed] [Google Scholar]
  10. John R., Jones M. K. An automated immunoradiometric assay for human thyrotropin. Clin Chem. 1984 Aug;30(8):1396–1398. [PubMed] [Google Scholar]
  11. Levi A. J., Sherlock S., Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet. 1968 Jun 15;1(7555):1275–1279. doi: 10.1016/s0140-6736(68)92292-7. [DOI] [PubMed] [Google Scholar]
  12. Olsen H., Mørland J. Ethanol-induced increase in procainamide acetylation in man. Br J Clin Pharmacol. 1982 Feb;13(2):203–208. doi: 10.1111/j.1365-2125.1982.tb01357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shenfield G. M. Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet. 1981 Jul-Aug;6(4):275–297. doi: 10.2165/00003088-198106040-00003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES